KYZATREX (testosterone undecanoate) by Marius Pharmaceuticals is androgens, including testosterone and dihydrotestosterone (dht), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. Approved for hypogonadism. First approved in 2022.
Drug data last refreshed 20h ago
androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis, and scrotum; the…
Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism
Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism
Worked on KYZATREX at Marius Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo